About
Optina Diagnostics is a healthcare technology company based in Montreal, Canada, that specializes in the early, non-invasive detection of diseases through advanced retinal imaging and artificial intelligence. Founded in 2011, the company focuses on brain health, particularly the early diagnosis of Alzheimer's disease by analyzing retinal biomarkers. The core technology, Retinal Deep Phenotyping™ (RDP™), utilizes a hyperspectral retinal camera and proprietary machine-learning algorithms to extract unique features from retinal images. This technology correlates with cerebral amyloid status, allowing for earlier detection of Alzheimer's compared to traditional methods. The company's hyperspectral retinal camera received FDA 510(k) clearance in February 2020, and its awAIr™-CAS test has been designated as a Breakthrough Device by the FDA, currently undergoing validation studies. Optina Diagnostics aims to make brain health assessments more accessible by integrating retinal imaging and AI into routine eye clinics. The company envisions expanding its platform to address other systemic and age-related diseases, enhancing patient outcomes in neurodegenerative conditions.
Technologies
Keywords
Company Information
-
Employees 26
-
Founded 2011
-
Annual Revenue $1500000
-
Total Funding $363667421
Location
8200 Boulevard Decarie, Montreal, Quebec, Canada, H4P 2P5
